Brunhild Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-07-2024
- Paid Up Capital ₹ 0.10 M
as on 31-07-2024
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 8.03%
(FY 2023)
- Profit 28.04%
(FY 2023)
- Ebitda 29.92%
(FY 2023)
- Net Worth -32.82%
(FY 2023)
- Total Assets 54.53%
(FY 2023)
About Brunhild Pharmaceuticals
The Corporate was formerly known as Coguire Web Venture Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Dsilva and Ganesan Iyer serve as directors at the Company.
- CIN/LLPIN
U74900MH2010PTC198897
- Company No.
198897
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2010
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Naigaon, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Brunhild Pharmaceuticals Private Limited offer?
Brunhild Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Infective API, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antifungal Injection, Tablet & Syrup, Common Disease Medicines, IV Fluids, Ayurvedic,Herbal Products & Medicine.
Who are the key members and board of directors at Brunhild Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Dsilva  | Director | 14-Jan-2010 | Current |
| Ganesan Iyer | Director | 14-Jan-2010 | Current |
Financial Performance of Brunhild Pharmaceuticals.
Brunhild Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.03% increase. The company also saw a substantial improvement in profitability, with a 28.04% increase in profit. The company's net worth observed a substantial decline by a decrease of 32.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brunhild Pharmaceuticals?
In 2023, Brunhild Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Cygnus Health Care Specialities Private LimitedActive 19 years 7 monthsGanesan Iyer is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Brunhild Pharmaceuticals?
Unlock and access historical data on people associated with Brunhild Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brunhild Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brunhild Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
